IN181672B - - Google Patents

Info

Publication number
IN181672B
IN181672B IN1053CA1996A IN181672B IN 181672 B IN181672 B IN 181672B IN 1053CA1996 A IN1053CA1996 A IN 1053CA1996A IN 181672 B IN181672 B IN 181672B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Orville G Kolterman
Robert G Thompson
John F Mullane
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of IN181672B publication Critical patent/IN181672B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1053CA1996 1995-06-07 1996-06-07 IN181672B (en])

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists

Publications (1)

Publication Number Publication Date
IN181672B true IN181672B (en]) 1998-08-29

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1053CA1996 IN181672B (en]) 1995-06-07 1996-06-07

Country Status (19)

Country Link
US (2) US6143718A (en])
EP (1) EP0772451B1 (en])
JP (1) JP4009319B2 (en])
AT (1) ATE228849T1 (en])
AU (1) AU721489B2 (en])
BG (1) BG101230A (en])
CA (1) CA2196999C (en])
CZ (1) CZ289043B6 (en])
DE (1) DE69625157T2 (en])
DK (1) DK0772451T3 (en])
ES (1) ES2187659T3 (en])
HU (1) HUP9700368A3 (en])
IN (1) IN181672B (en])
NO (1) NO970519L (en])
PT (1) PT772451E (en])
RU (1) RU2166958C2 (en])
SK (1) SK18697A3 (en])
WO (1) WO1996040220A1 (en])
ZA (1) ZA964838B (en])

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
SK31496A3 (en) * 1993-09-07 1998-06-03 Amylin Pharmaceuticals Inc Use of amylin, amylin agonists and amylin antagonists for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
AU760609B2 (en) * 1998-01-09 2003-05-15 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
DE60324387D1 (de) * 2002-01-08 2008-12-11 Amylin Pharmaceuticals Inc Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
EP1656368A4 (en) * 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
NZ543274A (en) * 2003-05-14 2007-12-21 Emisphere Tech Inc Compositions for delivering peptide YY and PYY agonists
EP1644027B1 (en) * 2003-07-16 2014-04-09 Evotec International GmbH Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
DE602005021858D1 (de) * 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
JP2007523196A (ja) * 2004-02-20 2007-08-16 ライナット ニューロサイエンス コーポレイション Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
AU2006223161B2 (en) * 2005-03-11 2011-05-12 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2007088479A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
NL2000464C2 (nl) * 2006-02-02 2007-09-11 Rinat Neuroscience Corp Werkwijzen voor het behandelen van ongewenst gewichtsverlies of eetstoornissen door het toedienen van een TRKB-agonist.
KR20090091181A (ko) * 2006-12-20 2009-08-26 리나트 뉴로사이언스 코퍼레이션 자가면역 장애의 치료를 위한 티로신 수용체 키나아제 ｂ 작용제
AU2007360979B2 (en) * 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
JP5536053B2 (ja) * 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． 離型剤を有するオクトレオチドインプラント
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
NZ595021A (en) * 2009-03-12 2013-04-26 Nordic Bioscience As Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
PL3345593T3 (pl) 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
TW201625671A (zh) * 2014-09-04 2016-07-16 諾佛 儂迪克股份有限公司 新穎澱粉素及降鈣素受體促效劑
DK3229828T5 (da) 2014-12-12 2024-10-14 Sanofi Aventis Deutschland Formulering med fast forhold mellem insulin glargin og lixisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
MD960317A (ro) * 1991-11-19 1998-05-31 Anylin Pharmaceuticals, Inc. Noile peptide-agoniste ale amilinei şi utilizarea lor
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
SK31496A3 (en) * 1993-09-07 1998-06-03 Amylin Pharmaceuticals Inc Use of amylin, amylin agonists and amylin antagonists for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Also Published As

Publication number Publication date
AU721489B2 (en) 2000-07-06
JP4009319B2 (ja) 2007-11-14
WO1996040220A1 (en) 1996-12-19
NO970519L (no) 1997-04-07
BG101230A (en) 1997-10-31
SK18697A3 (en) 1998-02-04
US6143718A (en) 2000-11-07
CZ289043B6 (cs) 2001-10-17
US6417164B1 (en) 2002-07-09
ES2187659T3 (es) 2003-06-16
EP0772451B1 (en) 2002-12-04
EP0772451A4 (en) 1998-09-30
NO970519D0 (no) 1997-02-05
ATE228849T1 (de) 2002-12-15
PT772451E (pt) 2003-04-30
RU2166958C2 (ru) 2001-05-20
CA2196999C (en) 2012-09-04
HUP9700368A3 (en) 2001-03-28
DE69625157T2 (de) 2003-04-17
HU9700368D0 (en) 1997-04-28
JPH10503785A (ja) 1998-04-07
CZ33797A3 (en) 1997-07-16
AU6268596A (en) 1996-12-30
EP0772451A1 (en) 1997-05-14
HUP9700368A2 (hu) 1998-06-29
ZA964838B (en) 1997-02-24
DK0772451T3 (da) 2003-01-06
CA2196999A1 (en) 1996-12-19
DE69625157D1 (de) 2003-01-16

Similar Documents

Publication Publication Date Title
DE69638352D1 (en])
DE69637714D1 (en])
BR122012014331A2 (en])
BRPI9612258B1 (en])
BRPI9612138B1 (en])
CH0741373H1 (en])
DK0727898T3 (en])
BR7501503U (en])
BR7502120U (en])
ECSMU950076U (en])
DK126096A (en])
CN3033225S (en])
CN3034591S (en])
CN3030543S (en])
CN3031001S (en])
CN3031350S (en])
CN3031655S (en])
CN3031742S (en])
CN3031926S (en])
CN3032332S (en])
CN3032390S (en])
CN3032522S (en])
CN3032568S (en])
CN3032692S (en])
CN3035871S (en])